Data completeness
2/8 — Basic
MEPROBAMATE (meprobamate) by Bausch + Lomb is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Meprobamate is an oral tablet carbamate derivative indicated for short-term relief of anxiety disorders. It works by depressing activity in the thalamus and limbic system of the central nervous system, providing anxiolytic effects.
Pre-Launch
Pre-launch stage signals early commercial team assembly; hiring likely for brand management, market access, and launch planning roles as regulatory approval approaches.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on MEPROBAMATE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.